Physician
Oncology
Dr. Edward F. McClay, MD
|
|
Give Review
Doctor Edward F. McClay, MD works in the field of Oncology. He studied medicine at Temple University School of Medicine. He has 4 awards "America's Top Doctors", "Top Doctors:San Diego Area", "America's Top Doctors for Cancer" and "Top Doctors:Southern California". Edward McClay is a published physician as well. He has 64 publications published. The latest was: Phase I and pharmacokinetic study of intraperitoneal topotecan. Dr. Edward F. McClay accepts Medicare payments and is listed with Medicare.gov.
Publications
- Limited genomic heterogeneity of circulating melanoma Cells in advanced stage patients.
- Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic ...
- Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular Disease: are there safe and potentially effective treatments?
- The role of anti-tumor necrosis factor receptor agents in Cancer survivors revisited.
- Differences in clinical trial patient attributes and outcomes according to enrollment setting.
- Completely regressed cutaneous melanocytic lesion: was it benign or was it Malignant?
- Phase II trial of dendritic Cells loaded with antigens from self-renewing, proliferating autologous tumor Cells as patient-specific antitumor vaccines in patients with...
- Metastatic Melanoma in a patient with Clouston syndrome successfully treated with isolated hyperthermic limb perfusion.
- Systemic chemotherapy for the treatment of metastatic melanoma.
- Introduction: Melanoma: American and European perspectives on diagnosis and treatment.
- Adjuvant therapy for patients with high-risk Malignant melanoma.
- The effects of Delta(12)-PGJ(2) on malignant Cells.
- Tamoxifen modulation of cisplatin resistance in patients with metastatic Melanoma. A biologically important observation.
- Systemic chemotherapy for metastatic melanoma.
- Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung Cancer: analysis of CALGB phase III trial 9235.
- Phase I/II study of IV topotecan in combination with whole Brain radiation for the treatment of Brain metastases.
- A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small Cell lung ca...
- Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim Analysis.
- A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic Melanoma.
- Melanoma thickness and histology predict sentinel lymph node status.
- The effect of tamoxifen and cisplatin on the Disease-free and overall survival of patients with high risk malignant melanoma.
- Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.
- Characterization of a human melanoma Cell line with non-oestrogen receptor dependent tamoxifen resistance.
- A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel.
- Phase I and pharmacokinetic study of intraperitoneal topotecan.
- Characterization of a sustained-release delivery System for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix.
- The Dartmouth Regimen: gone or going strong?
- Synergy between tamoxifen and cisplatin in human melanoma Cells is dependent on the presence of antiestrogen-binding sites.
- A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic Melanoma.
- Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
- delta 12-ProstaGlandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
- Dose intensification of cisplatin chemotherapy through biweekly administration.
- Profiles of women age 30-39 and age less than 30 with epithelial ovarian Cancer.
- Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma Cells.
- A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
- High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.
- Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
- Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin.
- Phase I and pharmacokinetic study of intraperitoneal ormaplatin.
- Tamoxifen: is it useful in the treatment of patients with metastatic Melanoma?
- A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian Cancer.
- Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian Cancer cell lines.
- A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies.
- Phase I trial of cisplatin in combination with glutathione.
- A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian Carcinoma.
- Cardiac dysrhythmias associated with ophthalmic atropine.
- Physician's test ordering behavior as a function of justification of the test.
- Allergy-induced hepatic toxicity associated with dacarbazine.
- Frequency of occult residual Melanoma after excision of a clinically positive regional lymph node.
- Combination chemotherapy and hormonal therapy in the treatment of Malignant melanoma.
- Preoperative evaluation of the oncology patient.
- The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic Melanoma.
- Epidemiology of bone and soft tissue sarcomas.
- Immunotherapeutic approaches to the treatment of bone and soft tissue sarcomas.
- A review: intraperitoneal cisplatin in the management of patients with ovarian Cancer.
- Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.
- Intraperitoneal cisplatin-based chemotherapy for ovarian Carcinoma.
- Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian Cancer.
- Melanoma: new biology; new therapy.
- Effective combination chemo/hormonal therapy for Malignant melanoma: experience with three consecutive trials.
- Intraperitoneal therapy in the management of patients with ovarian Cancer.
- Pharmacokinetic study of intraperitoneal streptozotocin.
- Modulation of cisplatin resistance in human malignant melanoma Cells.
Schools
Temple University School Of Medicine
Tucson Hosps Med Ed Program
Thomas Jefferson University Hospital
Thomas Jefferson University
Temple University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California HMO
- Blue Cross Blue Shield of California PPO
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Delta Health System
- First Health (Coventry Health Care) PPO
- GEHA
- Blue & Gold HMO
- Community Care Network HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare Advantage PFFS
- SmartCare HMO
- Tricare
- WholeCare Network HMO
- HealthPartners
- Medicare MCR
- Molina
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- Blue Choice
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
Awards
- America's Top Doctors
- Top Doctors:San Diego Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
Education
-
Thomas Jefferson University -
Temple University School of Medicine
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1497727465 | |
| NPPES Provider LastName | MCCLAY | |
| NPPES Provider FirstName | EDWARD | |
| NPPES Provider ZIPCode | 920836016 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 359.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 6.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497727465 |
| Last Name Of The Provider | MCCLAY |
| First Name Of The Provider | EDWARD |
| View All |
Similar Doctors
|
|
Dr. Marsha G. Fink, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael W. Saville, MD
This Doctor is OpenDoctor Recommended.
|